Neuronetics Agreed To Acquire Greenbrook TMS In An All-stock Transaction
Portfolio Pulse from Benzinga Newsdesk
Neuronetics has agreed to acquire Greenbrook TMS in an all-stock transaction, creating a vertically-integrated organization for mental health treatment in the U.S. The deal is expected to increase revenue, achieve cost synergies, accelerate profitability, and strengthen the balance sheet.
August 12, 2024 | 11:15 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Neuronetics' acquisition of Greenbrook TMS is expected to significantly benefit the company by increasing revenue, achieving cost synergies, accelerating profitability, and strengthening the balance sheet.
The acquisition is expected to double the revenue scale, achieve $15 million in annualized cost savings, and make the combined company Adjusted EBITDA positive by 2025. These factors are likely to positively impact Neuronetics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100